Abstract
The paper is providing an overview of the scientific background for development of the novel immunotherapy option for melanoma patients. Ipilimumab, one of the anti-CTLA4 monoclonal antibodies, has successfully completed its clinical development program and is approved for the clinical use.
With very promising treatment outcomes, ipilimumab may offer a new and effective treatment option for the metastatic melanoma treatment